Vicriviroc
Vicriviroc Uses, Dosage, Side Effects, Food Interaction and all others data.
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
| Trade Name | Vicriviroc |
| Generic | Vicriviroc |
| Vicriviroc Other Names | Vicriviroc |
| Type | |
| Formula | C28H38F3N5O2 |
| Weight | Average: 533.6288 Monoisotopic: 533.2977601 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in HIV infection and viral infection.
How Vicriviroc works
Vicriviroc is a once daily oral inhibitor of CCR5. It noncompetitively binds to a hydrophobic pocket between transmembrance helices by the extracellular side of CCR5. This allosteric antagonism causes a conformational change in the protein preventing binding of gp120 to CCR5. This prevents the entry of HIV into the cell.
Innovators Monograph
You find simplified version here Vicriviroc
